Modulation of myocardial perfusion and vascular reactivity by pericardial basic fibroblast growth factor: Insight into ischemia-induced reduction in endothelium-dependent vasodilatation

Laham, Roger J.; Simons, Michael; Tofukuji, Motohisa; Hung, David; Sellke, Frank W.

doi:10.1016/s0022-5223(98)70055-8

Cited by 32 publications

(11 citation statements)

References 28 publications

(66 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Finally, the results presented here for VPF/VEGFinduced angiogenesis in normal adult tissues are relevant to and provide a baseline for studies of the angiogenic response induced by various cytokines in ischemic tissues. A number of investigators have administered VPF/VEGF and other cytokines in animal models of tissue ischemia (Bauters et al, 1994;Laham et al, 1998;Lopez et al, 1997Lopez et al, , 1998aLopez et al, , 1998bMack et al, 1998;Magovern et al, 1997;Pearlman et al, 1995;Sellke et al, 1998b;Takeshita et al, 1995;Ware and Simons, 1997). More recently these approaches have been extended to patients with coronary heart disease and lower limb ischemia Isner et al, 1998;Losordo et al, 1998;Sellke et al, 1998aSellke et al, , 1998bVan Belle et al, 1998;Witzenbichler et al, 1998).…”

Section: Pettersson Et Almentioning

confidence: 99%

Heterogeneity of the Angiogenic Response Induced in Different Normal Adult Tissues by Vascular Permeability Factor/Vascular Endothelial Growth Factor

Pettersson

et al. 2000

Laboratory Investigation

385

362

View full text Add to dashboard Cite

SUMMARY:Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) is an angiogenic cytokine with potential for the treatment of tissue ischemia. To investigate the properties of the new blood vessels induced by VPF/VEGF, we injected an adenoviral vector engineered to express murine VPF/VEGF 164 into several normal tissues of adult nude mice or rats. A dose-dependent angiogenic response was induced in all tissues studied but was more intense and persisted longer (months) in skin and fat than in heart or skeletal muscle (Յ3 weeks). The initial response (within 18 hours) was identical in all tissues studied and was characterized by microvascular hyperpermeability, edema, deposition of an extravascular fibrin gel, and the formation of enlarged, thin-walled pericyte-poor vessels ("mother" vessels). Mother vessels developed from preexisting microvessels after pericyte detachment and basement membrane degradation. Mother vessels were transient structures that evolved variably in different tissues into smaller daughter vessels, disorganized vessel tangles (glomeruloid bodies), and medium-sized muscular arteries and veins. Vascular structures closely resembling mother vessels and each mother vessel derivative have been observed in benign and malignant tumors, in other examples of pathological and physiological angiogenesis, and in vascular malformations. Together these data suggest that VPF/VEGF has a role in the pathogenesis of these entities. They also indicate that the angiogenic response induced by VPF/VEGF is heterogeneous and tissue specific. Finally, the muscular vessels that developed from mother vessels in skin and perimuscle fat have the structure of collaterals and could be useful clinically in the relief of tissue ischemia. (Lab Invest 2000, 80:99-115).

show abstract

Section: Pettersson Et Almentioning

confidence: 99%

Heterogeneity of the Angiogenic Response Induced in Different Normal Adult Tissues by Vascular Permeability Factor/Vascular Endothelial Growth Factor

Pettersson

et al. 2000

Laboratory Investigation

385

362

View full text Add to dashboard Cite

show abstract

“…Recently, the possibility of pericardial access to diagnose and treat diseases of the myocardium, coronary vessels, and conducting system (including arrhythmias) has been made feasible not only in the few patients who have a sufficiently large pericardial effusion, but also in the noneffusive, "dry" pericardium [3••, [4][5][6][7][8]. The latter-potentially in any patient with disease of cardiac structures, with or without pericardial disease-is possible both via a catheter passed through the right atrial appendage (so far only in experimental animals) [9], or a newly developed instrument, the PerDUCER (Comedicus, Central Heights, MN), which has the capability of entering the dry pericardium.…”

Section: Pericardial Access As a Therapeutic And Diagnostic Routementioning

confidence: 99%

Intrapericardial therapy and diagnosis

Spodick

2002

Curr Cardiol Rep

View full text Add to dashboard Cite

Diagnosis and treatment for the heart and virtually all its structures is becoming available via the pericardium. With or without pericardial effusion (formerly necessary for safe access), instruments that can enter the noneffusive pericardium are available and thoroughly tested experimentally, with human trials currently under way. Successful therapy includes antiarrhythmic, vasodilatory, angiogenic, and other gene-related modalities and agents that stimulate the pericardial mesothelium to exceed the normal production of many active substances.

show abstract

“…Catheter-based intramyocardial and intravascular delivery strategies are associated with rapid washout of the agent, which may have led to negative outcome of clinical trials. As an alternative to local intracoronary or direct myocardial injection methods, the pericardial space has been explored as a suitable delivery area to the heart [30,31]. Intrapericardial delivery has been performed in experimental animal models using a surgical and percutaneous transarterial or transventricular approaches.…”

Section: Technical Delivery Strategiesmentioning

confidence: 99%

“…Intrapericardial delivery has been performed in experimental animal models using a surgical and percutaneous transarterial or transventricular approaches. Laham et al [31] administered a single dose of bFGF (30 g, 2mg or saline) into the pericardial space of pigs three weeks after induction of myocardial ischemia by an ameroid constrictor. Both bFGF groups showed improved myocardial perfusion, regional function, and endothelium-dependent vasodilatation compared to the placebo group receiving saline.…”

Section: Technical Delivery Strategiesmentioning

confidence: 99%

Gene therapy for myocardial angiogenesis: Has it come of age?

Kantor

Altman

Simari

et al. 2000

Curr Atheroscler Rep

View full text Add to dashboard Cite

Vasculogenesis and angiogenesis are the processes responsible for the development of the circulatory system during embryonic and adult life. Vasculogenesis occurs during embryogenesis while angiogenesis refers to blood vessel formation from any preexisting vasculature. Postnatal angiogenesis resumes during reproduction, wound healing, and ischemia. Excess blood vessel formation may contribute to initiating and maintaining many diseases such as chronic inflammatory disorders, tumor growth, restenosis, and atherosclerosis. In contrast. insufficient blood vessel formation is responsible for tissue ischemia, as in coronary artery disease. An increasing number of patients with advanced coronary artery disease remain symptomatic despite maximal interventional, surgical or medical treatment. Ideally, they would benefit most from additional arterial blood supply to ischemic areas of myocardium. Therapeutic angiogenesis, the ability to induce the growth of new blood vessels, is one of the most intriguing new frontiers in interventional cardiology for this growing patient group. Several approaches are currently undergoing intensive experimental investigations or have already entered early clinical trials involving either local angiogenic peptide administration or the transfection of angiogenic genes. Gene therapy for therapeutic myocardial angiogenesis is the most promising synthesis of two emerging technologies. In the following article, we will review the fundamental pathophysiological concepts of gene-based angiogenic therapy, the technical approaches and delivery systems, and the results of the first clinical trials. We will also discuss the controversies and unresolved issues of this new revascularization therapy.

show abstract

Modulation of myocardial perfusion and vascular reactivity by pericardial basic fibroblast growth factor: Insight into ischemia-induced reduction in endothelium-dependent vasodilatation

Cited by 32 publications

References 28 publications

Heterogeneity of the Angiogenic Response Induced in Different Normal Adult Tissues by Vascular Permeability Factor/Vascular Endothelial Growth Factor

Heterogeneity of the Angiogenic Response Induced in Different Normal Adult Tissues by Vascular Permeability Factor/Vascular Endothelial Growth Factor

Intrapericardial therapy and diagnosis

Gene therapy for myocardial angiogenesis: Has it come of age?

Contact Info

Product

Resources

About